Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 ...

On top of that, in recent years, Vertex has proven that it has what it takes to expand into other treatment areas. The ...

Vertex Pharmaceuticals' late-stage pipeline. Vertex Pharmaceuticals' strategy is to develop medicines in areas with high ...

Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Click for ...

I’m upgrading Vertex to a "Neutral" rating after its sharp stock decline corrected prior valuation concerns, but risks remain substantial. Vertex balances mid-teens revenue growth with high-teens ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...

Event context and recent share performance Vertex Pharmaceuticals (VRTX) has recently drawn investor attention without a single clear news catalyst, as the stock shows a month return of about 1.5% and ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.

The bond market is speaking more loudly than the stock market about the likely direction of the Federal Reserve.

Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.05% to $470.52 Wednesday, on what proved to be an all-around mixed ...

The next 12 months will be important for the drugmaker.